DSM and Cerapedics Partner to Develop Peptide Enhanced Bone Graft

DSM and Cerapedics will partner to develop and manufacture next-generation peptide enhanced bone graft. The strategic partnership aligns DSM’s regenerative materials capabilities with proprietary synthetic small peptide technology developed by Cerapedics.

DSM’s bioceramic platform is a carbonated apatite matrix used in bone graft substitute applications, which will be combined with Cerapedics’ growth factor in this partnership. The partnership will run from concept through commercialization.

Source: DSM Biomedical